Please login to the form below
Olumiant
This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19. ... The ACTT-2 trial, which was sponsored by the US National Institute of Allergy and
Latest news
-
AbbVie, Amgen and Takeda team up for joint COVID-19 trial
This includes remdesivir, and Gilead is planning combination studies of the antiviral drug when taken alongside Eli Lilly’s JAK inhibitor Olumiant (baricitinib) and Actemra.
-
Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
with Eli Lilly’s JAK inhibitor Olumiant (baricitinib) and Actemra.
-
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
and rheumatoid arthritis drug Olumiant (baricitinib).
-
Incyte’s JAK inhibitor cream clears second eczema trial
The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for
-
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib).
More from news
Approximately 6 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Lilly’s Verzenio scores a win in early-stage breast cancer
- How will the events and exhibitions industry change post-Coronavirus?
- Researchers call on Pfizer to delay COVID-19 vaccine application
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- J&J advances COVID-19 vaccine into phase 3 testing
- FDA approves Roche’s Actemra COVID-19 trial
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Leadership and talent
- Covid-19 redefines rules of customer engagement
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Aurora extends exclusive collaboration with Patient Intelligence Panel (PIP Health)
PMHub
Madmicrobe Studios
MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...
Latest intelligence
- Leadership and talent
- Looking at the key objectives of running leadership programmes...
- Covid-19 redefines rules of customer engagement
- Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
Quick links
Infographics
